MedTrace Logo

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

NCT04030338 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2025-09-03

No results posted yet for this study

Summary

The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.

Conditions

Interventions

DRUG

18F-DCFPyL-iPSMA

Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.

DRUG

68Ga-HBED-iPSMA

Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA

DIAGNOSTIC_TEST

PET/CT scan

The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed

Sponsors & Collaborators

Principal Investigators

  • Heiko Schoder, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-19
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04030338 on ClinicalTrials.gov